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With over four million women presenting for prenatal care in the 
United States annually and current recommendations to offer aneuploidy 
testing to all, there is no doubt that advances in prenatal genetic testing 
will have an important impact on the health and well-being of women 
and their children. Translational genomic research over the past decade 
has vastly increased our knowledge of human health and disease, 
bringing the promise of improving the lives of patients through new 
medical technology. Initially used in adult testing indications, many of 
these technologies are finding a place in obstetrics as pregnant women 
and their partners now have access to a vast array of fetal testing 
options that dramatically influence the delivery of prenatal care. With 
the development of new molecular testing modalities, fetal cells can now 
be analyzed for dozens of genetic mutations in a single pass and provide 
rich genomic information that would be undetectable using conventional 
testing methods.1 The ability to conduct genetic tests on cell-free fetal  
† Assistant Professor of Surgery, Cleveland Clinic Lerner College of 
Medicine. Staff, Departments of OB/GYN, Bioethics, and Genomic 
Medicine Institute. M.D., Case Western Reserve University School of 
Medicine; M.A.; Fellow of the American Congress of Obstetricians and 
Gynecologists. 
1. See Lauren C. Sayres & Mildred K. Cho, Cell-Free Fetal Nucleic Acid 
Testing: A Review of the Technology and Its Applications, 66 
Obstetrical & Gynecological Surv. 431, 438 (2011); see F. Lucy 
Raymond et al., Molecular Prenatal Diagnosis: The Impact of Modern 
Technologies, 30 Prenatal Diagnosis 674, 674 (2010). 
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DNA in the maternal blood stream is paving the way for non-invasive 
diagnostic tests to become part of routine prenatal care. Direct-to-
consumer test offerings have become increasingly visible and accessible in 
conjunction with these advances, expanding the avenues by which 
women can obtain information about their pregnancies.2 It is not just 
innovation in clinical genetics that has affected antenatal care. Parallel 
advances in the fields of maternal-fetal medicine and neonatology are 
also influencing how new genetic tests become incorporated into the care 
of the pregnant woman, establishing new boundaries for optimizing in 
utero health using genetic science.  
The recent explosion of genetic science and technology has allowed 
innovative approaches for identifying and treating disease to become a 
clinical reality. While aimed at improving and preserving health, these 
advances produce some of the most profound ethical, legal, and social 
questions about how to integrate new technology into the healthcare and 
lives of patients. These questions are twofold, as they pertain not only to 
understanding the significance of personal genetic information but also 
to how such information can and should be used to guide fundamental 
choices about the self and family. Information about one’s genetic 
makeup leads to a host of interlaced ethical and pragmatic ramifications 
that spring from our limited understanding of how the presence of a 
mutation plays out over the course of one’s life. Despite a more 
sophisticated understanding of the human genome, it is striking that 
many of the ethical and practical challenges of genetic testing remain 
unresolved, such as the interpretation of personal risk from the 
identification of a genetic mutation, the privacy and confidentiality of 
genetic information, and the prediction of quality of life for those living 
with disease or disability.  
These existing dilemmas have magnified implications in women’s 
reproductive health and prenatal genetic testing. While genomic research 
has opened up new possibilities to assess fetal health, the sheer volume 
of information generated by prenatal testing has amplified the 
fundamental ethical, legal, and social conundrums that already exist for 
genetic testing in other areas of medicine. In the context of pregnancy, 
decisions regarding genetic testing of the developing fetus involve a 
complex calculus based largely on conjecture and uncertainty. As in the 
case of genetic testing for adults, it is necessary for the pregnant woman 
to weigh the benefits of accessing genetic information about the fetus 
against the disadvantages and limitations of that information. She must 
consider the well-being of the unborn child and, as such, must integrate 
a host of unknowns about disease severity, progression, and quality of 
 
2. Timothy Caulfield & Amy L. McGuire, Direct-to-Consumer Genetic 
Testing: Perceptions, Problems, and Policy Responses, 63 Ann. Rev. 
Med. 23, 24 (2012). 
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life for her future child.3 Given the rapid advance of medical technology, 
she is also faced with considering what therapies or other resources that 
do not exist in the present may be available in the future that could 
alleviate any pain or suffering resulting from a genetic condition. It is 
based on these considerations that she must make the critical decision to 
continue a pregnancy while planning for the birth of a child with a 
genetic condition, to take part in an experimental procedure that may 
influence neonatal outcomes, or to end the pregnancy.  
Because of the special maternal-fetal dyad of pregnancy, women are 
uniquely affected by fetal genetic information and the decisions this 
information invites. Choices about prenatal genetic testing are often a 
collaborative effort between expecting parents. Yet, due to the biology of 
reproduction and pregnancy, women have a distinct role and a specific 
interest in the integration of these tests into clinical practice. Although 
prenatal genetic tests are conducted to assess the health of the fetus, 
they are performed on the pregnant woman and, as a result, have direct 
implications for her health and well-being. It is critical to recognize that 
these implications extend far beyond collecting a maternal blood sample 
or fetal cells though an invasive in utero procedure. The decision to 
proceed with testing has the potential to produce a cascade of 
downstream tests and procedures during the pregnancy to further 
evaluate or manage fetal genetic findings. Additionally, as the fields of 
perinatology and neonatology are advancing in conjunction with genetic 
science, the decision to undergo testing may also affect intrapartum 
management in the delivery suite. Finally, genetic information or 
procedures conducted in response to that information may also influence 
future reproductive decision-making.  
Women are uniquely affected by advances in prenatal genetic tests 
in another significant way. The decision to proceed with or to decline 
testing is a very personal choice that weaves a woman’s most personal 
values and beliefs about self, pregnancy, and parenthood into her 
healthcare choices. However, these individualized choices about the 
pregnancy are often influenced by factors external to her. Many of a 
woman’s reproductive decisions are bound by laws, policies, clinical 
practice guidelines, and public opinion about what a pregnant woman 
should and can do during the pregnancy. Given the ramifications of all 
of these issues, it is critical to understand how advances in genetic 
technologies affect the health and lives of women.  
 
3. Anne Drapkin Lyerly et al., Risks, Values, and Decision Making 
Surrounding Pregnancy, 109 Obstetrics & Gynecology 979, 983 (2007); 
Ryan A. Harris et al., Decision Analysis of Prenatal Testing for 
Chromosomal Disorders: What Do the Preferences of Pregnant Women 
Tell Us?, 5 Genetic Testing 23, 29-30 (2001); Elena A. Gates, 
Communicating Risk in Prenatal Genetic Testing, 49 J. Midwifery & 
Women’s Health 220, 224 (2004).  
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I. The Evolution of Genetic Technologies 
To understand the evolution and salience of these issues, it is 
important to first understand how genetic technologies have evolved 
over the past fifty years. One category of prenatal genetic testing that 
has undergone important changes is the screening test. Screening tests 
provide information about the chance that a fetus has Down syndrome 
or other related chromosomal abnormalities.4 The advantage of screening 
tests is that they are performed by drawing a sample of blood from the 
mother without the use of more invasive procedures; thus, the pregnant 
woman can bypass the uncommon but real risks associated with 
chorionic villus sampling (CVS) and amniocentesis.5 When used as a 
triage mechanism, screening tests help to determine which women might 
benefit from definitive diagnostic testing, thus reducing the potential 
number of iatrogenic losses of chromosomally normal fetuses that could 
occur with generalized use of these procedures. Screening tests also have 
limitations. One limitation is the ability of the screen to detect all 
fetuses with an abnormal compliment of chromosomes, so that there is a 
chance of a screen-negative result in the context of an affected fetus. 
There is also the possibility of a false positive result, in which case the 
screen would indicate an increased risk of a chromosomal abnormality 
when the fetus has, in fact, a normal complement of chromosomes. Thus, 
this information can only be used to inform decisions about further 
testing.  
The first screening tests were developed in the late 1980s and 1990s. 
Initially, it was determined that the combination of three maternal 
serum chemicals (human chorionic gonadotropin, unconjugated estriol, 
and alpha-fetoprotein) conferred information about possible 
abnormalities caused by extra or missing chromosomes (referred to as 
“aneuploidy”).6 This test analyzing these three chemicals was known as 
the Triple Screen. In the years following, the Quadruple Screen was 
developed to increase detection rates with the addition of another 
maternal serum marker called inhibin A. Since that time, there has been 
a move towards earlier screening modalities. While the Triple and 
Quadruple Screens provided fetal risk information, they could not be 
 
4. Deborah A. Driscoll & Susan J. Gross, Screening for Fetal Aneuploidy and 
Neural Tube Defects, 11 Genetics Medicine 818, 818 (2009); Am. Coll. of 
Obstetricians & Gynecologists, ACOG Practice Bulletin No. 77: Screening 
for Fetal Chromosomal Abnormalities, 109 Obstetrics & Gynecology 
217 passim (2007). 
5. Faris Mujezinovic & Zarko Alfirevic, Procedure-Related Complications of 
Amniocentesis and Chorionic Villous Sampling: A Systematic Review, 110 
Obstetrics & Gynecology 687, 687, 692 (2007). 
 
6. Devereux N. Saller, Jr. & Jacob A. Canick, Current Methods of Prenatal 
Screening for Down Syndrome and Other Fetal Abnormalities, 51 Clinical 
Obstetrics & Gynecology 24, 26-27 (2008). 
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performed until after the fifteenth week of pregnancy. Thus, choices 
about the pregnancy following confirmatory diagnostic testing could not 
be made until well into the second trimester, a time when the choice to 
continue or terminate the pregnancy may have very different 
ramifications for the woman than if the decision had been made earlier 
in the pregnancy. First trimester aneuploidy screening is a new screening 
approach consisting of assessment of maternal serum markers in 
conjunction with sonographic measurement of the back of the fetal neck 
(also known as nuchal translucency).7 This new tool confers similar fetal 
genetic risk information regarding Down syndrome as the Triple and 
Quadruple Screen but can be performed as early as eleven weeks into 
gestation.8 Timed one month earlier than its second trimester 
counterparts, this new screening modality gives patients a wider range of 
options over the course of their prenatal care, including immediate 
diagnostic procedures in the initial weeks of pregnancy. 
Important advances have also taken place in another category: 
diagnostic testing. The procedures of CVS and amniocentesis were 
developed in the latter half of the twentieth century as ways to directly 
test fetal cells to confirm the presence or absence of a genetic condition. 
Both procedures involve inserting a needle into the pregnant woman’s 
uterus to access fetal or placental cells for testing. While amniocentesis 
cannot be performed until the second trimester of pregnancy, CVS can 
be performed in the first trimester.  
The procedures of CVS and amniocentesis have changed little over 
the decades since their development. What has changed, however, is the 
number of testing applications that can be performed using these 
procedural platforms. Initially, these diagnostic procedures were used to 
conduct analysis for a single genetic mutation (e.g., cystic fibrosis) or 
chromosomal abnormality (e.g., Down syndrome) at a time. The 
development of multiplex testing techniques then allowed assessment for 
multiple different single Mendelian mutations or fetal characteristics 
(e.g., gender) simultaneously.9 Further advances in genetic science have 
changed the basic paradigms of genetic conditions and shifted our 
perception of diseases away from the concept of their being monogenic in 
origin towards the idea that they often involve multiple genes in concert. 
 
7. Uma M. Reddy & Michael T. Mennuti, Incorporating First-Trimester 
Down Syndrome Studies into Prenatal Screening: Executive Summary of 
the National Institute of Child Health and Human Development Workshop, 
107 Obstetrics & Gynecology 167, 169 (2006); Uma M. Reddy & 
Ronald J. Wapner, Comparison of First and Second Trimester Aneuploidy 
Risk Assessment, 50 Clinical Obstetrics & Gynecology 442, 445 
(2007).  
8. Kevin Spencer, Aneuploidy Screening in the First Trimester, 145C Am. J. 
Med. Genetics Part C: Seminars Med. Genetics 18, 20 (2007). 
9. See The Council on Ethical & Judicial Affairs, Am. Med. Ass'n, Multiplex 
Genetic Testing, Hastings Ctr. Rep., July-Aug. 1998, at 15, 15. 
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As a result, there has been a move towards incorporating microarrays 
into prenatal care, allowing analysis to identify from tens to thousands 
of variants during a single testing process.10 Prenatal microarray testing 
is able to generate detailed genetic information that could not be 
detected using standard cytogenetic techniques. 
Until recently, diagnostic information about the fetus could only be 
obtained through invasive procedures such as CVS and amniocentesis. 
Now, non-invasive prenatal genetic diagnosis is changing conventional 
paradigms about accessing and using fetal genetic information to guide 
antepartum care. Performed by drawing a blood sample from the 
pregnant woman, it is anticipated that non-invasive prenatal genetic 
diagnosis will ultimately provide the same degree of diagnostic 
information as more invasive procedures while bypassing the physical 
risks to mother and fetus.11 The clinical potential for non-invasive 
prenatal genetic diagnosis is great. Studies show that pregnant women 
are very interested in using this new approach to prenatal genetic 
testing.12 Preliminary studies also show that including the option of non-
invasive prenatal genetic diagnosis increases women’s interest in and 
willingness to undergo prenatal genetic testing for a number of different 
conditions and also alters core beliefs about genetic testing in 
pregnancy.13 Access to genetic information via a sample of maternal 
blood is also likely to encourage the already growing direct-to-consumer 
movement of genetic testing, which may further complicate legal, ethical, 
and social ramifications. As the development of genetic, genomic, and 
molecular technologies concurrently accelerates, the scope of possible in 
utero investigations will drastically expand. 
II. The Impact of Advancing Genomic Technologies on 
Informed Decision-Making by Pregnant Women 
While research in the field of genetics has opened up new 
possibilities to assess fetal health, the sheer volume of information 
generated by prenatal testing generates a host of dilemmas, challenges, 
and questions. To date, many of these discussions have focused on the 
 
10. Ronald J. Wapner et al., Integration of Microarray Technology into 
Prenatal Diagnosis: Counselling Issues Generated During the NICHD 
Clinical Trial, 32 Prenatal Diagnosis 396, 399 (2012). 
11. Diana W. Bianchi et al. Genome-wide Fetal Aneuploidy Detection by 
Maternal Plasma DNA Sequencing, 119 Obstetrics & Gynecology 890, 
891, 900 (2012); Ruth M. Farrell & Patricia K. Agatisa, Preparing Patients 
for First Trimester Prenatal Aneuploidy Screening: Effective Education by 
Obstetric Providers Is Key (unpublished manuscript) (on file with author).  
12. Reana Tischler et al., Noninvasive Prenatal Diagnosis: Pregnant Women’s 
Interest and Expected Uptake, 31 Prenatal Diagnosis 1292, 1296-97 
(2011). 
13. Farrell & Agatisa, supra note 11. 
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health and well-being of the expectant child and, by so doing, have 
displaced considerations about the pregnant woman. Yet it is paramount 
that discussions address the impact of these technologies on women’s 
lives both during and after the pregnancy. This includes a discussion not 
only of the scientific and medical aspects of the newest technologies but 
also the expectations, moral obligations, values, and preferences 
surrounding genetic testing, motherhood, and family that are placed on 
women. Some of the issues are novel; they present women, healthcare 
providers, scientists, and policy makers with nuanced questions about 
the meaning, significance, and implications of acquiring detailed fetal 
genetic information during pregnancy. In some cases, these issues can be 
foreseen and, with adequate preparation, negative sequelae can be 
mitigated before the technology is broadly implemented. In other cases, 
the full ramifications of a new genetic technology do not become evident 
until that technology has been widely integrated into patient care. What 
is remarkable, however, is that still other issues have been lingering 
unresolved since the earliest stages of prenatal genetic testing. Of 
greatest concern, these pre-existing issues may be exacerbated by the 
introduction of new tests that provide more detailed information about 
the fetus.  
One set of issues pertains to a woman’s ability to make informed 
choices about her prenatal genetic testing options. With an expanding 
array of testing options, a pregnant woman must have the resources to 
make informed, value-reflective choices about her prenatal testing 
options. Without a mechanism to support her access, understanding, and 
considerations of this information, she is at risk for going down two 
equally negative paths. In one scenario, she may proceed with a prenatal 
genetic test without an adequate understanding of its indications, 
limitations, and implications, leaving her grossly underprepared to 
consider the outcomes of either ending the pregnancy or planning for the 
birth of a child with a genetic condition. In the other case, she may 
decline a test that might have otherwise been wanted because she did 
not understand how genetic information can potentially optimize 
outcomes for the expected child. Both scenarios can lead to weighty and 
significant implications for the health and well-being of the woman in 
the context of both the current pregnancy and future family building 
plans.  
Since the initial days of prenatal genetic testing, studies have shown 
that pregnant women have struggled to make informed, value-reflective 
decisions about their prenatal genetic testing choices. This trend has 
been evident for both screening and diagnostic tests. What is significant 
is that many of the same barriers to women’s education and decision-
making continue to persist even with ongoing advancement in prenatal 
applications of genetics. A core issue has been women’s ability to access 
patient-centered information about genetic diseases and the approaches 
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to identifying them.14 The priority for this kind of information is high 
because decisions to undergo or decline prenatal genetic testing are an 
individualized calculus requiring knowledge of the fetal genetic condition 
in question, approaches to identify it, and post-test choices for the 
pregnancy. In addition, these considerations must also incorporate 
personal values about disability and illness, parenthood, and quality of 
life. However, there are significant problems to the informed decision-
making process related to pregnant women’s knowledge of prenatal 
genetic testing, as the fundamental concepts associated with screening 
and diagnostic testing remain elusive to many.15 Barriers associated with 
a lack of health literacy and a limited understanding of the concepts of 
risk and probability also have a notable effect on minorities and women 
from lower educational and socioeconomic groups.16 
Contemporary studies provide important insight into how these pre-
existing barriers will pose even greater challenges for innovative ways to 
assess fetal health assessments. Using the first trimester aneuploidy 
screen as a litmus test for the readiness of the healthcare field to support 
women’s decision-making, it is evident that the same underlying 
problems that arose with the introduction of the Triple and Quadruple 
Screens continue to exist. For pregnant women, this manifests as deficits 
in understanding (1) the purpose of this new test, (2) the ways in which 
it differs from conventional tests, and (3) possible ways to navigate the 
expanded decision tree of post-test options for the pregnancy. For 
clinicians, there continue to be challenges in mobilizing adequate 
resources to support the decision-making process for new tests. The 
ongoing challenge for the healthcare provider to acquire and maintain 
knowledge of clinical genetics is another contemporary problem. These 
underlying problems stem not only from limitations of time and clinical 
resources to support patient education but also from the reality that it 
has become difficult for medical education to keep pace with advances in 
 
14. Id.; see, e.g., Miriam Kuppermann et al., Beyond Race or Ethnicity and 
Socioeconomic Status: Predictors of Prenatal Testing for Down Syndrome, 
107 Obstetrics & Gynecology 1087, 1096 (2006). 
15. Matthijs van den Berg et al., Informed Decision Making in the Context of 
Prenatal Screening, 63 Patient Educ. & Counseling 110, 115 (2006); 
Matthijs van den Berg et al., Are Pregnant Women Making Informed 
Choices about Prenatal Screening?, 7 Genetics Medicine 332, 336-37 
(2005); see generally Theresa M. Marteau & Elizabeth Dormandy, 
Facilitating Informed Choice in Prenatal Testing: How Well Are We 
Doing? 106 Am. J. Med. Genetics 185 (2001). 
 
16. Sandra Suther & Gebre-Egziabher Kiros, Barriers to the Use of Genetic 
Testing: A Study of Racial and Ethnic Disparities, 11 Genetics Medicine 
655, 661-62 (2009); B. Khoshnood et al., Women's Interpretation of an 
Abnormal Result on Measurement of Fetal Nuchal Translucency and 
Maternal Serum Screening for Prenatal Testing of Down Syndrome, 28 
Ultrasound Obstetrics & Gynecology 242, 247 (2006). 
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genetic science.17 In addition, although some degree of uncertainty has 
been a long-standing component in choices about prenatal genetic tests, 
such as questions about subsequent disease severity and impact on 
quality of life, microarray testing has made uncertainty a much stronger 
presence in the decision-making process. With the ability to identify 
thousands of genetic variants, some with as-yet-unknown relevance for 
health, women struggle to reconcile the meaning of an abnormal result 
with choices about the pregnancy.18 Because the core leading medical, 
ethical, and personal implications of accessing fetal genetic information 
remain constant with all forms of prenatal genetic testing, these issues 
must be addressed both for already established forms of testing as well 
those innovative approaches positioned to be broadly integrated into 
prenatal care. Without the recognition of these issues and mobilization 
of resources to address them, pregnant women will be vulnerable to the 
hazards of uninformed decision-making.  
III. The Voluntary Nature of Decisions about  
Prenatal Genetic Testing 
Access to accurate, patient-centered information is only one 
component of a pregnant woman’s preparedness to make informed 
choices about prenatal genetic testing. Equally important is her ability 
to make voluntary decisions about whether to proceed or decline forms 
of testing. Discussions early in the development of prenatal genetic 
testing brought attention to the voluntary nature of decision-making and 
the need to ensure that women were positioned to make autonomous 
choices about their testing options. Leading scholars paved the way to 
examining the meanings and implications of the “good mother,” 
including the expectations and obligations for or against testing placed 
on her during pregnancy by healthcare professionals, society, and 
 
17. Sandy Suther & Patricia Goodson, Barriers to the Provision of Genetic 
Services by Primary Care Physicians: A Systematic Review of the 
Literature, 5 Genetics Medicine 70, 75-76 (2003); see Susan B. Trinidad 
et al., Educational Needs in Genetic Medicine: Primary Care Perspectives, 
11 Community Genetics 160, 160 (2008); Charles J. Macri et al., 
Implementation and Evaluation of a Genetics Curriculum to Improve 
Obstetrician-gynecologist Residents' Knowledge and Skills in Genetic 
Diagnosis and Counseling, 193 Am. J. Obstetrics Gynecology 1794, 
1797 (2005); see Caulfield & McGuire, supra note 2, at 25. 
 
18. See Sean E. Lipinski et al., Uncertainty and Perceived Personal Control 
Among Parents of Children with Rare Chromosome Conditions: The Role 
of Genetic Counseling, 142C Am. J. Med. Genetics Part C: Seminars 
Med. Genetics 232, 232 (2006); see generally R. Alta Charo & Karen H. 
Rothenberg, "The Good Mother": The Limits of Reproductive 
Accountability and Genetic Choice, in Women and Prenatal Testing: 
Facing the Challenges of Genetic Technology 105, 105-30 (Karen 
H. Rothenberg & Elizabeth J. Thompson eds., 1994). 
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family.19 On the one hand, there were cautions for utilizing genetic tests, 
raising the specter of eugenics and devaluing those individuals living 
with illness and disease. On the other, there were warnings against 
restricting a woman’s autonomy and autonomous decision-making. 
Concepts of coercion and non-directive counseling are at the heart of 
these discussions. While coercion is often conceptualized as overtly 
directed counseling, it can also be more subtle in nature, such as when 
information is withheld or biased. As decisions regarding testing during 
pregnancy align closely with a woman’s personal beliefs, these 
discussions also brought to light that the voluntary nature of decisions 
can be eroded by healthcare providers who may not be aware of her 
individual and cultural preferences about pregnancy, motherhood, 
disability, and illness.  
Over the past several decades, there has been a move not only to 
develop tests that can generate a vast amount of genetic information 
about the pregnancy but also to provide these data with the lowest risk 
possible to the fetus. In response, new approaches to prenatal genetic 
testing are being developed to fulfill these criteria. This new cohort of 
tests reawakens interest in voluntariness in prenatal genetic testing and 
provokes foundational discussions addressing women’s abilities to make 
unhindered choices about their use.20 For many women, the iatrogenic 
risks of CVS and amniocentesis served as a barrier to accessing fetal 
genetic information. Now, the real possibility of gaining diagnostic level 
information through a maternal blood draw stands to fundamentally 
change the risk-benefit calculus that women undertake when considering 
testing as an option. At the present, non-invasive diagnosis is emerging 
as a tool to assess fetal risk for chromosomal abnormalities. However, its 
potential for expanded genomic testing is great and, in the coming years, 
it is expected that its techniques can be applied to search for a number 
of different genetic variants simultaneously. In removing the medical 
risks of diagnostic testing, it is important to safeguard the protections of 
 
19. See generally Barbara Katz Rothman, The Tentative Pregnancy: Then and 
Now, in Women and Prenatal Testing: Facing the Challenges of 
Genetic Technology 260 (Karen H. Rothenberg & Elizabeth J. 
Thompson eds., 1994); see Abby Lippman, The Genetic Construction of 
Prenatal Testing: Choice, Consent, or Conformity for Women?, in 
Women and Prenatal Testing: Facing the Challenges of Genetic 
Technology 9 (Karen H. Rothenberg & Elizabeth J. Thompson eds., 
1994); Charo & Rothenberg, supra note 18; Karen H. Rothenberg, Genetic 
Accountability and Pregnant Women, 7 Women’s Health Issues 215 
(1997). 
20. Zuzana Deans & Ainsley J. Newson, Should Non-Invasiveness Change 
Informed Consent Procedures for Prenatal Diagnosis?, 19 Health Care 
Analysis 122 (2011); see Dagmar Schmitz et al., An Offer You Can't 
Refuse? Ethical Implications of Non-Invasive Prenatal Diagnosis, 10 
Nature Revs. Genetics 515, 515 (2009). 
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informed consent, including the voluntary aspects of a woman’s choice to 
proceed with or decline testing.  
Because the leading medical, ethical, and personal implications of 
accessing fetal genetic information remain the same for all forms of 
diagnostic testing (whether invasive or non-invasive), an important part 
of the translational process will be to ensure every pregnant woman has 
the resources to make informed, value-reflective choices about her 
prenatal testing options. Thus, there is a need for contemporary 
discussions to revisit the issues of voluntariness, to recognize issues 
pertinent to women’s autonomous decision-making within the current 
context of prenatal genetics, and to construct mechanisms to ensure that 
pregnant women are not coerced with regards to genetic testing.  
IV. Maternal-Fetal Surgery and the Changing 
Calculus of Prenatal Genetic Testing  
The evolution of prenatal genetic testing technology is not taking 
place in a vacuum. Contemporary discussions must also consider the 
discipline of obstetrics and how changes in this field have an undeniable 
impact on how the ethical, legal, and social implications of prenatal 
genetic tests take shape. The great majority of these procedures remain 
experimental, and many more studies must be performed before they 
become part of standard practice. However, the possibility and 
availability of interventions to ameliorate the sequelae of a genetic 
condition in utero will begin to shift how the benefits and limitations of 
the available prenatal genetic tests are framed by patients and their 
healthcare providers.  
It is important to recognize the discordance between what can be 
diagnosed in utero using genetic tests and what can be done to prevent 
or mitigate the illness associated with a genetic mutation. Despite 
advances in genetic science, procedures to effectively alter DNA-level 
mutations to prevent disease or, in many cases, control the effects of a 
genetic variant on an individual’s phenotype have yet to be developed. 
Because of these limitations, pregnant women have customarily been 
given two options following in utero diagnosis of a genetic condition. 
One option was pregnancy termination, most often performed in the 
second trimester of pregnancy after the testing process was completed. 
For women who did not elect for or were unable to access abortion 
services, another option was to continue the pregnancy and plan for the 
birth of a child with a genetic condition.  
For many women, the potential of being put in the position of 
having to decide between these dichotomous outcomes was a key reason 
for declining testing. Yet advances in the field of high-risk obstetrics and 
fetal intervention have begun to alter the choices presented to pregnant 
women. Together with the efforts to advance clinical genetics, there has 
been a growing interest in interventions during pregnancy to improve 
fetal and neonatal outcomes. Maternal-fetal surgeries entail conducting 
surgery on the pregnant woman, procedures which entail making an 
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incision in the woman’s abdomen and uterus to access the fetus. While 
the risks of these procedures to fetus and mother are clearly identifiable, 
their benefits overall remain unclear. Recent data about a procedure to 
correct neural tube defects in utero may mark a pivotal point in how 
prenatal genetic testing is presented to women. One of the functions of 
screening tests is to identify the risk of neural tube defects, which are 
errors in how the early nervous system takes shape. The primary 
approach to management of pregnancies included heightened antepartum 
surveillance and plans for intervention after birth. A recent study shows 
that surgical management of a specific type of neural tube defect 
(myelomeningocele) in utero may lead to improve outcomes for some 
children, though more research must be conducted. However, this 
procedure comes at a cost, as it presents serious medical risks to the 
pregnant woman.21 Yet the mere availability of this option for those 
women whose pregnancies have been diagnosed with a neural tube defect 
fundamentally changes how the utility of prenatal genetic testing will be 
framed.  
This maternal-fetal surgery addresses just one of the thousands of 
genetic conditions that can now be diagnosed in utero. The reality is 
that, while the past decade has witnessed the growth of prenatal genetic 
testing technology, there has not been parallel expansion of pregnant 
patients’ post-testing options. As a result, pregnant women continue to 
grapple with the dilemmas that come with the many ways to diagnose a 
multitude of different genetic conditions while having very few proven 
therapeutic options either during pregnancy or after birth. Thus, an 
important part of discussions about the impact of new prenatal genetic 
tests is recognizing that an expanding discordance is developing between 
what can be identified in utero and current options to change outcomes 
for the child. The result is a new and nuanced set of ethical, legal, and 
social dilemmas for women as they face their prenatal genetic testing 
options.  
Conclusion  
Some of the most profound, difficult, and controversial questions 
regarding women, motherhood, family, children, and disability exist at 
the intersection of obstetric and clinical genetics. Advances in molecular 
genetics intensify of our uncertainties and, in some cases, our discomfort 
with the ability of genetic technology to affect our lives and the world in 
which we live. The quickly changing and increasing analytical 
capabilities of genomic applications in the prenatal clinical context 
invoke the need to evaluate the ethical, legal, and social implications of 
 
21. See N. Scott Adzick et al., A Randomized Trial of Prenatal Versus 
Postnatal Repair of Myelomeningocele, 364 New Eng. J. Med. 993, 1002-
04 (2011). 
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these issues for those pregnant women in the position of considering 
prenatal testing.  
In 1991, the National Institutes of Health sponsored a workshop 
entitled “Reproductive Genetic Testing: Impact upon Women” to begin 
to address some of these core issues. Led by Elizabeth Thomson and 
Karen Rothenberg, the workshop’s mission was to examine the impact of 
prenatal genetic testing on the lives of women and to identify a set of 
themes to guide the development and use of these technologies. This 
meeting was a landmark event because it was the first of its kind to 
bring together a multidisciplinary panel of experts to examine advances 
in prenatal genetic testing within the context of women’s lives. 
A host of events have taken place in the past twenty years that have 
changed the landscape of prenatal genetic testing and the care of women 
during pregnancy. As discussed here, these events have taken place not 
only in genetic science and the practice of obstetrics but also in 
discussions and policies about the delivery of prenatal care, women’s 
reproductive rights, informed decision-making, and disability. Some of 
these advances provoke new and unexplored questions about how to 
integrate advances in clinical genetics into the care of pregnant women. 
At the same time, other cornerstone issues associated with genetic 
testing, such as defining and identifying illness and disease in addition to 
the implications of fetal genetic information, remain unchanged and as 
provocative today as they were twenty years ago. Given the accelerating 
trajectory of clinical genetics, medical science, and surgical innovation, it 
is critical to revisit how the lives of women are uniquely affected by the 
newest approaches to prenatal care.  
In response to this need, the Case Western Reserve University 
School of Law hosted a symposium entitled, “New Technologies, New 
Challenges: Women and Prenatal Genetic Testing in the 21st Century.” 
The aim of the symposium was to bring together a group of leading 
experts from the disciplines of bioethics, social science, clinical medicine, 
law, and genetic science to identify those challenges and critically 
examine how the health and lives of women are affected by the advances 
taking place in the care of pregnant women. Scholars who participated in 
the original 1991 conference joined in collaborative dialogue with new 
leaders in the field, generating a solid foundation for understanding the 
breadth and depth of these issues as they have evolved over the past 
twenty years. Over the course of a day and a half, important strides 
were made toward understanding the unique ways in which women’s 
lives are affected by advances in genetic technology and the carryover of 
these effects for children, families, and the practice of medicine. As the 
emergence of new genetic technologies accelerates in the months and 
years to come, it will be vital that multidisciplinary experts continue to 
engage in examining the challenges associated with prenatal genetic tests 
and forming ethical guidelines for their translation into patient care.  
